BHV-1450 / Biohaven - LARVOL DELTA

BHV-1450, an Ig-G4 selective MODE degrader, mitigates anti-Dsg3-mediated skin damage implicated in Pemphigus vulgaris (AAD 2026) - "Treatment with BHV-1450, both prophylactically and therapeutically, demonstrated efficacy in rescuing the disease phenotype. BHV-1450 showed potency in vitro and in vivo, as well as efficacy in a disease phenotype in vivo, and was optimized for the treatment of IgG4-AIDs, including PV."

CNS Disorders • Dermatology • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Myasthenia Gravis • Pemphigus Vulgaris • Thrombocytopenic Purpura • ASGR • MUC4